TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03293017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 10 MG
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 10 MG
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam 10 MG
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 30mg
Description: Baclofen 30 mg/day given over three gifts daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 60mg
Description: Baclofen 60 mg/day given over three gifts daily
Study: NCT04086121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for SC injection
Study: NCT03967041

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological defined sarcopenia
Description: Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological defined sarcopenia
Description: Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
Study: NCT02317484

Intervention type: DRUG
Intervention: Ipragliflozin (SGLT2 inhibitor)
Study: NCT03202446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Glycated Chitosan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Glycated Chitosan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photothermal Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photothermal Laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT03507985

Intervention type: OTHER
Intervention: Two tests evaluating memory and attention
Description: The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap

Intervention type: OTHER
Intervention: Two tests evaluating memory and attention
Description: The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap
Study: NCT02360488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Therapy
Description: 18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Clinic Therapy
Description: 18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
Study: NCT00005067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo photodynamic therapy
Study: NCT02413632

Intervention type: OTHER
Group type: OTHER
Intervention: creation of a STIs score risk
Description: 4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)

Intervention type: OTHER
Group type: OTHER
Intervention: validation of a STIs score risk
Description: DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
Study: NCT03705286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVAC-PU-ETT
Description: Placement of a EVAC-PU-ETT in the setting of emergent intubation.
Study: NCT02890355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03705286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC-ETT
Description: Placement of a PVC-ETT in the setting of emergent intubation.
Study: NCT04208672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UMindSleep
Description: CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
Study: NCT02841358

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biopsy
Study: NCT00000256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80% N2O
Study: NCT03161067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiCNS
Description: Surgical implantation
Study: NCT02833064

Intervention type: RADIATION
Intervention: Non-contrast magnetic resonance imaging

Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis

Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis

Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis

Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis

Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis
Study: NCT02426034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApatinibTablets
Description: Apatinib Tablets, recommended dose of 850mg
Study: NCT00292253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebif® via Rebiject™Mini
Description: Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rebif® via manual injections
Description: Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
Study: NCT02711358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin suppositories
Description: The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
Study: NCT02837393

Intervention type: PROCEDURE
Intervention: Ureteral catheterization
Description: During ureteral catheterization, urine samples will be obtain from each kidney

Intervention type: PROCEDURE
Intervention: Ureteral catheterization
Description: During ureteral catheterization, urine samples will be obtain from each kidney
Study: NCT01624285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02890355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03881605

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI screening
Description: A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
Study: NCT02194894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen will be given for patient for both arms for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen will be given for patient for both arms for 14 days
Study: NCT03945071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal plug
Description: Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
Study: NCT01635621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Description: Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Description: Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Description: Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
Study: NCT02182986

Intervention type: PROCEDURE
Intervention: transplant
Description: All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).

Intervention type: PROCEDURE
Intervention: transplant
Description: All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).

Intervention type: DRUG
Intervention: Immunosuppressive Drugs
Description: Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.

Intervention type: DRUG
Intervention: Immunosuppressive Drugs
Description: Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
Study: NCT00738426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ML Scanner (MLS)
Description: Red diode low level laser light energy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: non-therapeutic light energy output
Study: NCT01213446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition.
Study: NCT03339713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Fluarix will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Fluarix will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
Study: NCT01395810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
Study: NCT00490919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system
Description: Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal system (placebo) worn for 7 days
Study: NCT03770026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline cervical flushing
Description: Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine Autologous platelet-rich plasma
Description: Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
Study: NCT04265261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo matched to RG7774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7774
Description: Participants will receive oral RG7774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7774
Description: Participants will receive oral RG7774
Study: NCT02660684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Injection or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Injection or oral
Study: NCT01865656

Intervention type: OTHER
Group type: OTHER
Intervention: Skills training
Description: Refresher training on Basic Emergency Obstetric and Newborn care

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency obstetric drills
Description: Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia

Intervention type: OTHER
Group type: OTHER
Intervention: Revised Case Sheets
Description: Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive supervision
Description: Quarterly supportive supervision visits each of the intervention first referral units.

Intervention type: OTHER
Group type: OTHER
Intervention: Referral strengthening
Description: To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
Study: NCT01863615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Roaccutan 2 capsules of 20 mg; reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Roaccutan 2 capsules of 20 mg; reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Oratane 2 capsules of 20 mg; test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Oratane 2 capsules of 20 mg; test drug
Study: NCT03074461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Side-to-End Anastomosis
Description: During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Coloplasty
Description: During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
Study: NCT04316260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation e-visit
Description: electronic visits (e-visits) for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
Study: NCT03271632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: Infusion of multi-CAR T cells
Study: NCT00826410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redon drain
Description: subcutaneous suction drain after laparotomy for two days
Study: NCT02232477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human alpha iduronidase
Description: Intrathecal recombinant human alpha iduronidase every 3 months
Study: NCT01932749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Study: NCT02000622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Study: NCT04271202

Intervention type: DRUG
Group type: OTHER
Intervention: Emgality 120 MG in 1 ML Prefilled Syringe
Description: Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.